{
    "Rank": 658,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00006260",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CWRU4196"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA043703",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA043703"
                        },
                        {
                            "SecondaryId": "CWRU-4196"
                        },
                        {
                            "SecondaryId": "BMS-CRWU-4196"
                        },
                        {
                            "SecondaryId": "NCI-G00-1854"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Case Comprehensive Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer",
                "OfficialTitle": "A Phase II Study Of An OutPatient Three Day VIP Regimen With Oral Mesna For Metastatic Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "June 2010",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "May 1997"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "January 2005",
                    "PrimaryCompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 11, 2000",
                "StudyFirstSubmitQCDate": "January 26, 2003",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "January 27, 2003",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "June 9, 2010",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 11, 2010",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Scot C. Remick, MD",
                    "ResponsiblePartyOldOrganization": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Case Comprehensive Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Drugs such as mesna may be effective in preventing some of the side effects of chemotherapy.\n\nPURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of etoposide and ifosfamide given with mesna, and cisplatin in treating patients who have metastatic breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nDetermine the objective response rate in patients with metastatic breast cancer treated with etoposide, ifosfamide with mesna, and cisplatin.\nDetermine the tolerability and toxicity of this regimen in these patients.\n\nOUTLINE: Patients are stratified according to number of prior chemotherapy courses for metastatic disease (0 vs 1).\n\nPatients receive etoposide IV over 60-90 minutes, cisplatin IV over 30 minutes, and ifosfamide IV over 30 minutes on days 1-3. Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.\n\nPatients are followed every 3 months.\n\nPROJECTED ACCRUAL: At least 36 patients (16 per stratum) will be accrued over 36 months."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IV breast cancer",
                        "recurrent breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "36",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "cisplatin",
                            "InterventionDescription": "cisplatin IV over 30 minutes on days 1-3."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "etoposide",
                            "InterventionDescription": "etoposide IV over 60-90 minutes on days 1-3."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "ifosfamide",
                            "InterventionDescription": "ifosfamide IV over 30 minutes on days 1-3."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Mesna",
                            "InterventionDescription": "Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Determine the objective response rate in patients with metastatic breast cancer treated with etoposide, ifosfamide with mesna, and cisplatin.",
                            "PrimaryOutcomeTimeFrame": "Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression."
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically proven progressive metastatic breast cancer\n\nMeasurable disease\n\nAny lesion measurable in 2 dimensions\nHepatic metastases if the sum of the measurements below the costal margin in the midclavicular line and the tip to the xiphoid process is greater than 5 cm during quiet respiration\nHepatic defects that are clearly measurable by radionuclide, CAT, or MRI scans\nBone metastases are not considered measurable disease\nEvaluable disease allowed if measurable disease also present\nNo brain metastases, carcinomatous meningitis, or spinal cord compression\n\nHormone receptor status:\n\nNot specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\nNot specified\n\nMenopausal status:\n\nNot specified\n\nPerformance status:\n\nECOG 0-2\n\nLife expectancy:\n\nAt least 3 months\n\nHematopoietic:\n\nHemoglobin at least 10 g/dL\nWBC at least 4,000/mm3\nPlatelet count at least 100,000/mm3\n\nHepatic:\n\nBilirubin no greater than 2.0 mg/dL\n\nRenal:\n\nCreatinine no greater than 1.5 mg/dL\nNo bladder outlet obstruction\n\nCardiovascular:\n\nNo symptomatic cardiovascular disease (e.g., congestive heart disease) or inability to tolerate a fluid load\n\nOther:\n\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo active infection\nNo prior malignancies except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\nNo greater than 1 prior biologic response modifier treatment for metastatic disease\n\nChemotherapy:\n\nNo greater than 1 prior chemotherapy regimen for metastatic disease allowed\nPatients who relapsed during or within 6 months after adjuvant chemotherapy are considered to have failed 1 regimen\nPatients who relapsed more than 6 months after adjuvant chemotherapy are considered to not have had a prior regimen\nGreater than 4 weeks since prior chemotherapy (greater than 6 weeks for mitomycin or nitrosoureas) and recovered\nNo prior cisplatin, etoposide, or ifosfamide\n\nEndocrine therapy:\n\nPrior medical or surgical hormonal therapy allowed\n\nRadiotherapy:\n\nPrior radiation therapy to areas of measurable disease allowed if indicator lesion increased in size by greater than 25% after treatment\nRecovered from effects of prior radiotherapy\n\nSurgery:\n\nRecovered from effects of major surgery\n\nOther:\n\nAt least 7 days since prior nephrotoxic drugs (e.g., aminoglycosides, diuretics, lithium, intravenous contrast, or nonsteroidal antiinflammatory drugs)",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "StdAgeList": {
                    "StdAge": [
                        "Child",
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Scot C. Remick, MD",
                            "OverallOfficialAffiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "LocationCity": "Cleveland",
                            "LocationState": "Ohio",
                            "LocationZip": "44106-5055",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "ReferenceList": {
                    "Reference": [
                        {
                            "ReferencePMID": "24028306",
                            "ReferenceType": "derived",
                            "ReferenceCitation": "Viana LV, Leitao CB, Grillo MF, Rocha EP, Brenner JK, Friedman R, Gross JL. Hypertension management algorithm for type 2 diabetic patients applied in primary care. Diabetol Metab Syndr. 2013 Sep 12;5(1):52. doi: 10.1186/1758-5996-5-52."
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000005047",
                            "InterventionMeshTerm": "Etoposide"
                        },
                        {
                            "InterventionMeshId": "D000007069",
                            "InterventionMeshTerm": "Ifosfamide"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000000972",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Phytogenic"
                        },
                        {
                            "InterventionAncestorId": "D000059005",
                            "InterventionAncestorTerm": "Topoisomerase II Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000059003",
                            "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000018906",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
                        },
                        {
                            "InterventionAncestorId": "D000000477",
                            "InterventionAncestorTerm": "Alkylating Agents"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M7881",
                            "InterventionBrowseLeafName": "Etoposide",
                            "InterventionBrowseLeafAsFound": "Use of",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M5872",
                            "InterventionBrowseLeafName": "Cisplatin",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M341584",
                            "InterventionBrowseLeafName": "Etoposide phosphate",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9807",
                            "InterventionBrowseLeafName": "Ifosfamide",
                            "InterventionBrowseLeafAsFound": "Required",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M17501",
                            "InterventionBrowseLeafName": "Mesna",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M230774",
                            "InterventionBrowseLeafName": "Isophosphamide mustard",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20632",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3510",
                            "InterventionBrowseLeafName": "Alkylating Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}